ECONOMIC BENEFIT OF FARICIMAB COMPARED TO AFLIBERCEPT 8MG IN TREATING PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION OR DIABETIC MACULAR EDEMA IN THE UNITED STATES

被引：0
|
作者：
Tabano, D. [1 ]
El Moustaid, F. [1 ]
Rosettie, K. L. [1 ]
Ko, S. [1 ]
Meer, E. [2 ]
Brodie, F. L. [2 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE25
引用
收藏
页码：S61 / S61
页数：1
相关论文
共 50 条
  • [1] Costs of novel 8 mg aflibercept and faricimab compared to 2mg aflibercept and bevacizumab for neovascular age-related macular degeneration and diabetic macular edema at 2 years
    Sood, Shefali
    Vail, Daniel
    Berkowitz, Sean
    Zhang, Casey
    Coovadia, Zaheer
    Budhu, Uma
    Friedman, Scott
    Parikh, Ravi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [2] Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
    Liberski, Slawomir
    Wichrowska, Malgorzata
    Kociecki, Jaroslaw
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [3] Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
    Desideri, Lorenzo Ferro
    Traverso, Carlo Enrico
    Nicolo, Massimo
    Munk, Marion R.
    PHARMACEUTICS, 2023, 15 (05)
  • [4] RELATIVE EFFECTIVENESS OF FARICIMAB VS AFLIBERCEPT 8 MG AFTER LOADING PHASE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA
    Buhrer, C.
    Tabano, D.
    Cox, O.
    VALUE IN HEALTH, 2023, 26 (12) : S47 - S47
  • [5] Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema
    Diack, Cheikh
    Avery, Robert L.
    Cheung, Chui Ming Gemmy
    Csaky, Karl G.
    Gibiansky, Leonid
    Jaminion, Felix
    Gibiansky, Ekaterina
    Sickert, Denise
    Stoilov, Ivo
    Cosson, Valerie
    Bogman, Katrijn
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2024, 13 (11):
  • [6] Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1646): : 45 - 46
  • [7] BUDGET IMPACT ANALYSIS OF FARICIMAB FOR TREATING PATIENTS WITH DIABETES MACULAR EDEMA OR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN PANAMA
    Hidalgo, J.
    Ordonez, J.
    Avlia, P.
    Munoz, J. M.
    VALUE IN HEALTH, 2023, 26 (06) : S93 - S93
  • [8] BUDGET IMPACT ANALYSIS OF FARICIMAB FOR TREATING PATIENTS WITH DIABETES MACULAR EDEMA OR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN GUATEMALA
    Hidalgo, J.
    Ordonez, J.
    Deutschmann, B.
    Arriola, A.
    Del Cid, J. M.
    Bustamante, W. Makepeace
    VALUE IN HEALTH, 2023, 26 (06) : S159 - S159
  • [9] ECONOMIC BURDEN OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA IN COLOMBIA
    Robles, A.
    Gil Rojas, Y.
    Amaya, D.
    Sardi Correa, C.
    Hernandez, F.
    VALUE IN HEALTH, 2022, 25 (12) : S71 - S72
  • [10] Outcomes of Intravitreal Aflibercept 8 mg in Eyes With Neovascular Age-Related Macular Degeneration Previously Treated With Faricimab
    Momenaei, Bita
    Yonekawa, Yoshihiro
    Abril, Paige
    Mccullough, Rachel
    Abbey, Ashkan M.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2025,
12345